Acute pancreatitis: A two-year update on epidemiology, clinical diagnosis, treatment, and outcomes

Abstract Acute pancreatitis (AP) is an acute inflammatory disease with a continually increasing burden and a highly heterogeneous clinical course. The disease is self-limiting in most patients, but some may progress to persistent organ failure and infected pancreatic necrosis and be left with long-term pancreatic functional impairment. Treatment of AP remains based on supportive care, and evidence from the past two years has primarily redefined the patient populations for established interventions, treatment intensity, and timing of implementation. Risk stratification and the level of monitoring should be based on serial assessment of organ function and the patient’s response to initial treatment, rather than on a single score. Early treatment emphasizes goal-directed, moderate-intensity fluid resuscitation in patients with hypovolemia, timely analgesia, and resumption of oral feeding once tolerated; enteral nutrition should be used when intake is inadequate, with stepwise advancement to the target energy intake. A specific sequential regimen of selective cyclooxygenase-2 inhibitors has shown potential to improve AP outcomes, but adequately validated early pharmacologic interventions capable of slowing disease progression remain lacking. For infected pancreatic necrosis, delayed intervention remains the preferred strategy when the condition is controllable; in patients who require intervention, the minimally invasive step-up pathway and timing of debridement should be selected according to clinical status, necrotic burden, and local anatomy. Meanwhile, increasing attention is being paid to etiology-specific recurrence prevention and stratified follow-up for post-AP diabetes, pancreatic exocrine insufficiency, persistent symptoms, and functional recovery, driving a shift in AP management from a single hospitalization to care across the disease course, spanning the acute phase, recovery, and long-term follow-up. From an evidence-based perspective, this narrative review summarizes new evidence from the past two years on the epidemiology, clinical diagnosis and risk stratification, acute-phase treatment, management of local complications, recurrence prevention, and long-term outcomes of AP.

Authors

Publication Details

Journal
Journal of Pancreatology
Published
2026-11-12
DOI
https://doi.org/10.1097/jp9.0000000000000286
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Acute pancreatitis: A two-year update on epidemiology, clinical diagnosis, treatment, and outcomes

Yin Zhu, Yaoyu Zou, Jianhua Wan
Journal of Pancreatology
Pancreatitis Pathology and Treatment
article

Acute pancreatitis: A two-year update on epidemiology, clinical diagnosis, treatment, and outcomes

Yin Zhu, Yaoyu Zou, Jianhua Wan
article en

Abstract

Abstract Acute pancreatitis (AP) is an acute inflammatory disease with a continually increasing burden and a highly heterogeneous clinical course. The disease is self-limiting in most patients, but some may progress to persistent organ failure and infected pancreatic necrosis and be left with long-term pancreatic functional impairment. Treatment of AP remains based on supportive care, and evidence from the past two years has primarily redefined the patient populations for established interventions, treatment intensity, and timing of implementation. Risk stratification and the level of monitoring should be based on serial assessment of organ function and the patient’s response to initial treatment, rather than on a single score. Early treatment emphasizes goal-directed, moderate-intensity fluid resuscitation in patients with hypovolemia, timely analgesia, and resumption of oral feeding once tolerated; enteral nutrition should be used when intake is inadequate, with stepwise advancement to the target energy intake. A specific sequential regimen of selective cyclooxygenase-2 inhibitors has shown potential to improve AP outcomes, but adequately validated early pharmacologic interventions capable of slowing disease progression remain lacking. For infected pancreatic necrosis, delayed intervention remains the preferred strategy when the condition is controllable; in patients who require intervention, the minimally invasive step-up pathway and timing of debridement should be selected according to clinical status, necrotic burden, and local anatomy. Meanwhile, increasing attention is being paid to etiology-specific recurrence prevention and stratified follow-up for post-AP diabetes, pancreatic exocrine insufficiency, persistent symptoms, and functional recovery, driving a shift in AP management from a single hospitalization to care across the disease course, spanning the acute phase, recovery, and long-term follow-up. From an evidence-based perspective, this narrative review summarizes new evidence from the past two years on the epidemiology, clinical diagnosis and risk stratification, acute-phase treatment, management of local complications, recurrence prevention, and long-term outcomes of AP.

Journal of Pancreatology
Good health and well-being
Pancreatitis Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon